Sharekhan's research report on Cadila Healthcare
Cadila Healthcare’s (Cadila) Q4FY2021 numbers were healthy and earnings beat estimates, due to a tax credit and an adjustment for a one-time impairment expenses. Cadila is in a sweet spot, wherein both its geographies, India and the US have an improved growth outlook. Efforts to build a portfolio of Covid drugs including Vaccines augurs well from a growth perspective.
Outlook
We retain our Buy recommendation on the stock with unchanged PT of Rs. 720
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More